Clinical trial NCT00294164: Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
Official title: Phase 2/3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Safety and Efficacy Trial of Subcutaneously Administered Serostim® (Mammalian Cell-derived Recombinant Human Growth Hormone, r-hGH) in the Treatment of Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
Human Immunodeficiency Virus Infections
Keywords: Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
Human Immunodeficiency Virus Infections
recombinant human growth hormone (r-hGH)
Serostim®
Placebo
Lead sponsor: EMD Serono
Sponsor class: INDUSTRY
First posted: 2006-02-20
Enrollment: 245
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a Phase 2/3, multicenter, double-blind, randomized, parallel-group, placebo-controlled, dose-finding trial of Serostim® (mammalian cell-derived recombinant human growth hormone, r-hGH) versus placebo in subjects with human immunodeficiency virus-associated adipose tissue redistribution syndrome (HARS).

The primary study objective is to determine whether Serostim® treatment reduces adipose tissue maldistribution more effectively than placebo. The primary co-endpoints are derived from measures of visceral adipose tissue assessed by computerized tomography (CT) and the ratio of trunk; and limb fat assessed by dual-energy X-Ray absorptiometry (DXA) scans. Anthropometric measures, physical exams, quality of life assessments, serial photographs, and various laboratory measures will be used to address secondary objectives. These secondary objectives relate to the impact of Serostim® on Physician and subject assessments of change in body shape, health-related quality of life, attitude towards medication compliance, metabolic markers, fat redistribution, and safety.

On Day 1, eligible subjects will be randomized in a 1:1:1 ratio to receive daily Serostim®, Serostim® and placebo given on alternate days, or daily placebo. Serostim® doses will be based on body weight, with a maximum dose of 4 milligram (mg).

Therapy will continue for 12 weeks. Treatment will then be altered and the new treatment will be continued through Week 24. Interim Study Visits will be required at Weeks 2 and 4 (Treatment Period 1) and at Weeks 14 and 16 (Treatment Period 2). Subjects will be offered to be enrolled into a maintenance Protocol (Study 23056) at Week 24.


Eligibility criteria: Inclusion Criteria:

• Have an Human Immunodeficiency Virus (HIV) infection documented either by viral load as measured by polymerase chain reaction (PCR) amplification; or by the presence of HIV antibodies with confirmation by one of the following:

* Western blot
* Immunofluorescence assay
* Branched Deoxyribonucleic Acid (bDNA) signal amplification
* The presence of p24 antigen

These tests may have been performed at any time in the past, but the results must be available for review by the Serono monitor prior to randomization

* Have evidence of excess abdominal adipose deposition when measured using the following cut points:

  * Men: Waist circumference greater than 88.2 centimeter (cm) and waist/hip ratio greater than or equal to 0.95
  * Women: Waist circumference greater than 75.3 cm and waist/hip ratio greater than or equal to 0.9 (23)
* Be taking antiretroviral medication(s) which is (are) approved or is (are) available under a treatment investigational new drug (IND). The regimen must have remained stable for the 30 days prior to study entry. Subjects must also have agreed not to discontinue or to change their regimen for the duration of the study except as judged medically necessary
* Have parameter values less than the following limits:

  * Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and amylase less than or equal to 3 times the upper limit of normal (Screening)
  * Fasting triglycerides less than or equal to 1,000 milligram per deciliter (mg/dL) (Screening)
  * Fasting glucose less than 110 mg/dL (Screening)
  * Two hour (120 minute) glucose less than 140 mg/dL (following an oral glucose load at Screening)
* Weigh greater than or equal to 36 kilogram (kg) (79.3 pound)
* Be between 18 and 60 years of age unless local law dictates different limits
* Be able and willing to comply with the protocol for the duration of the study
* Have given written informed consent
* If female, be post-menopausal or surgically sterilized (that is, have undergone tubal ligation or hysterectomy), or is

  * Using a contraceptive method such as a hormonal contraceptive, intra uterine device, diaphragm with spermicide, or condom with spermicide, for the duration of the study
  * Not pregnant or breast feeding

Exclusion Criteria:

* Have an active acquired immune deficiency syndrome (AIDS)-defining Opportunistic Infection (OI) as defined by the Center for Disease Control; or have had an untreated or suspected serious systemic infection, or persistent fever greater than or equal to 101 degree Fahrenheit (°F) (38.3 degree Celsius) during the 30 days prior to study entry
* Have any active malignancy, except for localized cutaneous Karposi's sarcoma (fewer than 10 lesions, none of which are larger than 2 cm, and not on active therapy)
* Have a central nervous system (CNS) mass or active CNS process associated with neurological findings
* Have unstable or untreated hypertension, defined as greater than or equal to 140/90 millimeter of mercury (mmHg) at the time of the Screening Visit, and/or has initiated or changed antihypertensive therapy in the 30 days prior to Day 1
* Have an acute critical illness treated in an intensive care unit, for example, due to complications following open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure
* Have any condition, which interferes with informed consent or protocol compliance including, but not limited to, active substance abuse and/or dementia
* Is unable to comply with the concomitant therapy restrictions
* Have ever been diagnosed with any of the following conditions:

  * Pancreatitis
  * Carpal tunnel syndrome (unless resolved by surgical release)
  * Diabetes mellitus
  * Angina pectoris
  * Coronary artery disease
  * Any disorder associated with moderate to severe edema (for example, cirrhosis, nephrotic syndrome, congestive heart failure, lymphedema)
* Allergy or hypersensitivity to growth hormone

Primary outcomes:
measure: Change from Baseline in absolute area of visceral adipose tissue quantified by Computerized Tomography (CT) scan at Week 12
timeFrame: Baseline and Week 12
measure: Change from Baseline in the ratio of trunk fat to limb fat quantified by Dual-Energy X-Ray Absorptiometry (DXA) scan at Week 12
timeFrame: Baseline and Week 12
Secondary outcomes:
measure: Change from Baseline in composite sum of the visceral adipose tissue and the ratio of trunk fat to limb fat at Week 12
timeFrame: Baseline and Week 12
measure: Dorsal fat area in the transverse plane, as measured by Computerized Tomography (CT) Scan
timeFrame: Baseline, Week 12 and 24
measure: Weight measured on a calibrated scale
timeFrame: Baseline, Week 12 and 24
measure: Absolute values of maximal chest, waist, and hip circumference
timeFrame: Baseline, Week 12 and 24
measure: Waist/hip ratio
timeFrame: Baseline, Week 12 and 24
measure: Absolute value of dorsocervical fat
timeFrame: Baseline, Week 12 and 24
measure: Absolute value of total body fat as quantified by DXA scan
timeFrame: Baseline, Week 12 and 24
measure: Absolute value of trunk and Limb fat quantified by DXA scan
timeFrame: Baseline, Week 12 and 24
measure: Absolute value of Lean body mass as quantified by DXA scan
timeFrame: Baseline, Week 12 and 24
measure: Absolute concentration of serum insulin and glucose
timeFrame: Baseline, Week 12 and 24
measure: Absolute concentration of fasting serum triglyceride, total cholesterol, Low density lipoprotein (LDL), High density lipoprotein (HDL) and very low density lipoprotein (VLDL)
timeFrame: Baseline, Week 12 and 24
measure: High density lipoprotein (HDL)/Low density lipoprotein (LDL) ratio
timeFrame: Baseline, Week 12 and 24
measure: Change from Baseline in Serial Photography Parameters of chest and abdomen at Week 12 and 24
timeFrame: Baseline, Week 12 and 24
measure: Health related Quality of life
timeFrame: Baseline, Week 4, 12 and 24
Other outcomes:
Locations:
Study officials:
affiliation: EMD Serono
name: Ellen Brady, M.D. MPH
role: STUDY_DIRECTOR
References:
citation: Kotler DP, Muurahainen N, Grunfeld C, Wanke C, Thompson M, Saag M, Bock D, Simons G, Gertner JM; Serostim in Adipose Redistribution Syndrome Study Group. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):239-52. doi: 10.1097/00126334-200403010-00004.